BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 35125405)

  • 1. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
    Stasenko M; Feit N; Lee SSK; Shepherd C; Soslow RA; Cadoo KA; Alektiar K; Da Silva EM; Martins Sebastião AP; Leitao MM; Gardner G; Selenica P; Abu-Rustum NR; Weigelt B; Mueller JJ
    Int J Gynecol Cancer; 2020 Jun; 30(6):717-723. PubMed ID: 32376737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTNNB1 p.D32A (c.95A > C) somatic mutation in stage I grade 1 endometrioid endometrial carcinoma with lung metastasis: a case report.
    Zhong L; Jiang W; RutieYin ; Liu H; Song L
    BMC Med Genomics; 2023 Jun; 16(1):137. PubMed ID: 37328769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Significance of International Federation of Gynecology and Obstetrics Grading in Microsatellite Instability-High and POLE-Mutant Endometrioid Endometrial Carcinoma.
    Kertowidjojo E; Momeni-Boroujeni A; Rios-Doria E; Abu-Rustum N; Soslow RA
    Mod Pathol; 2023 Sep; 36(9):100234. PubMed ID: 37268062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
    Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
    Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
    Rudd ML; Hansen NF; Zhang X; Urick ME; Zhang S; Merino MJ; ; Mullikin JC; Brody LC; Bell DW
    PLoS One; 2022; 17(1):e0251286. PubMed ID: 35081118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. POLE exonuclease domain mutations in endometrial carcinoma: a case report.
    Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E
    Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.
    Matrai CE; Ohara K; Eng KW; Glynn SM; Chandra P; Chatterjee-Paer S; Motanagh S; Mirabelli S; Kurtis B; He B; Sigaras A; Gupta D; Chapman-Davis E; Holcomb K; Sboner A; Elemento O; Ellenson LH; Mosquera JM
    Int J Gynecol Pathol; 2022 May; 41(3):207-219. PubMed ID: 34483300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrioid Endometrial RNA Index Predicts Recurrence in Stage I Patients.
    Nief CA; Hammer PM; Wang A; Charu V; Tanweer A; Litkouhi B; Kidd E; Gentles AJ; Howitt BE
    Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38669067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling of primary endometrioid endometrial cancer and matched lung metastases:
    Gordhandas S; Da Cruz Paula A; Kertowidjojo EC; Pareja F; Dessources K; da Silva EM; Derakhshan F; Mueller JJ; Abu-Rustum NR; Herman Chui M; Weigelt B
    Gynecol Oncol Rep; 2024 Jun; 53():101391. PubMed ID: 38633674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theories of endometrial carcinogenesis: a multidisciplinary approach.
    Sherman ME
    Mod Pathol; 2000 Mar; 13(3):295-308. PubMed ID: 10757340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study.
    Sharma AE; Moran A; Somasegar S; Steinhardt G; Chapel DB; Lastra RR; Lee NK; Ritterhouse LL; Bennett JA
    Int J Gynecol Pathol; 2023 Jan; 42(1):26-34. PubMed ID: 35125405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.